Karl O Mäki (Otto Mäki)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Randomized Controlled Trial

Coronavirus Disease

Health Promotion

Top Venues

Health communication

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Linda Cecilia Karlsson, Karl O Mäki, Dawn Liu Holford, Angelo Fasce, Philipp Schmid, Stephan Lewandowsky, Anna Soveri
Testing Psychological Inoculation to Reduce Reactance to Vaccine-Related Communication. Health communication (2024)
Karl O Mäki, Linda C Karlsson, Johanna K Kaakinen, Philipp Schmid, Stephan Lewandowsky, Jan Antfolk, Anna Soveri
COVID-19 and influenza vaccine-hesitancy subgroups. PloS one 19 (7) (2024)
Karl O Mäki, Linda C Karlsson, Johanna K Kaakinen, Philipp Schmid, Stephan Lewandowsky, Jan Antfolk, Anna Soveri
COVID-19 and influenza vaccine-hesitancy subgroups. PloS one 19 (7) (2024)
Karl O Mäki, Linda C Karlsson, Johanna K Kaakinen, Philipp Schmid, Stephan Lewandowsky, Jan Antfolk, Anna Soveri
Tailoring interventions to suit self-reported format preference does not decrease vaccine hesitancy. PloS one 18 (3) (2023)
Karl O Mäki, Linda C Karlsson, Johanna K Kaakinen, Philipp Schmid, Stephan Lewandowsky, Jan Antfolk, Anna Soveri
Tailoring interventions to suit self-reported format preference does not decrease vaccine hesitancy. PloS one 18 (3) (2023)
Angelo Fasce, Linda Cecilia Karlsson, Pierre Verger, Karl O Mäki, Frederike Taubert, Amanda Garrison, Philipp Schmid, Dawn Liu Holford, Stephan Lewandowsky, Fernanda Rodrigues, Cornelia Betsch, Anna Soveri
Endorsement of alternative medicine and vaccine hesitancy among physicians: A cross-sectional study in four European countries. Human vaccines & immunotherapeutics 19 (2) (2023)
Karl O Mäki, Linda C Karlsson, Johanna K Kaakinen, Philipp Schmid, Stephan Lewandowsky, Jan Antfolk, Anna Soveri
Tailoring interventions to suit self-reported format preference does not decrease vaccine hesitancy. PloS one 18 (3) (2023)